Olga Pozdnyakova

Olga Pozdnyakova

Auto-generated profile, based on publicly available information

Olga Pozdnyakova

Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
DNDamodaran Narayanan
Damodaran Narayanan
OPOlga Pozdnyakova
Olga Pozdnyakova
RHRobert P. Hasserjian
Robert P. Hasserjian
SPSanjay Patel
Sanjay Patel
OWOlga K. Weinberg
Olga K. Weinberg
The clinicopathologic features of DNA methyltransferase 3A (DNMT3A)-mutated de novo acute myeloid leukemia (AML), and the significance of variant type, variant allele frequency (VAF), and multiple concomitant DNMT3A mutations, remain poorly defined. We examined 104 DNMT3A-mutated de novo AML patients from 2 major centers. Most (82%) had normal karyotype (NK); R882H variants were frequent(38%). The most commonly comutated genes included nucleophosmin (NPM1; 53%), Fms-related tyrosine kinase 3 (FLT3)–internal tandem duplication (25%), IDH1 (23%), IDH2 (23%), and TET2 (21%). Patients with high DNMT3A VAF at diagnosis (≥44%; DNMT3AHIGH) had more significant leukocytosis and higher blast counts in peripheral blood and bone marrow. DNMT3AHIGH cases were associated with much shorter event-free survival (EFS; 14.1 vs 56.8 months) and overall survival (OS; 18.3 months vs not reached) compared with cases of patients with low DNMT3A (DNMT3ALOW). Thirteen patients had 2 DNMT3A variants and similar VAFs at diagnosis that tracked together at multiple time points after chemotherapy and/or stem cell transplantation (SCT). In multivariable analyses performed in NK patients who received standard induction chemotherapy, presence of 2 DNMT3A mutations (hazard ratio [HR] = 3.192; P = .038) and SCT in first complete remission (HR = 0.295; P = .001) independently affected EFS; increasing marrow blast percentage (HR = 1.026; P = .025), high DNMT3A VAF (HR = 3.003; P = .010), and 2 DNMT3A mutations (HR = 4.816; P = .020) had independent effects on OS. These data support the adverse prognostic significance of DNMT3AHIGH reveal a novel association between 2 concomitant DNMT3A mutations and inferior outcome in DNMT3A-mutated de novo AML with a NK.

14 March 2024 in Blood
Verified
Journal Article
Closed access
PDF file
PBPavan K. Bendapudi
Pavan K. Bendapudi
SNSumaiya Nazeen
Sumaiya Nazeen
JRJustine Ryu
Justine Ryu
OSOnuralp Söylemez
Onuralp Söylemez
ARAlissa K Robbins
Alissa K Robbins
JLJulie-Aurore Losman
Julie-Aurore Losman
Extreme disease phenotypes can provide key insights into the pathophysiology of common conditions, but studying such cases is challenging due to their rarity and the limited statistical power of existing methods. Herein, we used a novel approach to pathway–based mutational burden testing, the rare variant trend test (RVTT), to investigate genetic risk factors for an extreme form of sepsis-induced coagulopathy, infectious purpura fulminans (PF). In addition to prospective patient sample collection, we electronically screened over 10.4 million medical records from 4 large hospital systems and identified historical cases of PF for which archived specimens were available to perform germline whole-exome sequencing. We found a significantly increased burden of low-frequency, putatively function-altering variants in the complement system in patients with PF compared with unselected patients with sepsis (P = .01). A multivariable logistic regression analysis found that the number of complement system variants per patient was independently associated with PF after controlling for age, sex, and disease acuity (P = .01). Functional characterization of PF-associated variants in the immunomodulatory complement receptors CR3 and CR4 revealed that they result in partial or complete loss of anti-inflammatory CR3 function and/or gain of proinflammatory CR4 function. Taken together, these findings suggest that inherited defects in CR3 and CR4 predispose to the maladaptive hyperinflammation that characterizes severe sepsis with coagulopathy.

27 April 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
EMEmily F. Mason
Emily F. Mason
OPOlga Pozdnyakova
Olga Pozdnyakova
MRMikhail Roshal
Mikhail Roshal
AFAmir Fathi
Amir Fathi
ESEytan M. Stein
Eytan M. Stein
MSMichael R. Savona
Michael R. Savona

17 October 2025 in Blood Advances
Verified
Journal Article
Open access
WWWaihay J. Wong
Waihay J. Wong
RZRebecca L. Zon
Rebecca L. Zon
CGChristopher J. Gibson
Christopher J. Gibson
CHCaleb Ho
Caleb Ho
OPOlga Pozdnyakova
Olga Pozdnyakova
BEBenjamin L. Ebert
Benjamin L. Ebert
Myelodysplastic syndrome (MDS) is driven by genetic mutations, but diagnosis relies on morphologic evaluation of bone marrow hematopoiesis. Only a small number of genetic abnormalities define specific bone marrow morphologic features in MDS, such as SF3B1 mutations and deletions of chromosome 5q. We hypothesized that additional genetic alterations are associated with specific dysplastic morphologic features in MDS. We assessed genetic-morphologic associations between commonly mutated genes and 10 morphologic features in a cohort of MDS bone marrows with a high degree of dysplasia. We replicated the association of SF3B1 mutations with ring sideroblasts and found that dysplastic megakaryocytes with separated nuclei were independently associated with STAG2 and/or ASXL1 mutations. In addition, STAG2 mutations were associated with abnormal myeloid nuclear segmentation and myeloid cell hypogranulation. These findings demonstrate that STAG2 and ASXL1 mutations are associated with specific morphologic abnormalities in MDS.

10 December 2020 in Blood
Verified
Journal Article
Open access
PDF file
DNDamodaran Narayanan
Damodaran Narayanan
OPOlga Pozdnyakova
Olga Pozdnyakova
Damodaran Narayanan, Olga Pozdnyakova; Marked dysgranulopoiesis mimicking disseminated histoplasmosis, Blood, Volume 136, Issue 24, 10 December 2020, Pages 2838

11 February 2021 in Blood
Verified
Journal Article
Open access
PDF file
CHChristopher B. Hergott
Christopher B. Hergott
OPOlga Pozdnyakova
Olga Pozdnyakova
Christopher B. Hergott, Olga Pozdnyakova; Beware the “other AML”: hepatic angiomyolipoma with extensive extramedullary hematopoiesis, Blood, Volume 137, Issue 6